VA launches semaglutide alcohol use disorder trial

The United States — United States Department of Veterans Affairs announced on July 31, 2026, the launch of a nationwide clinical trial to evaluate whether semaglutide, a GLP-1 receptor agonist marketed by Novo Nordisk as Ozempic and Wegovy, can treat alcohol use disorder in veterans. The trial, named Cessation or Reduction of Alcohol Consumption in Veterans (CRAVE), will enroll more than 600 veterans aged 18-80 with moderate or severe alcohol use disorder at 18 VA medical centers. Participants will receive weekly injections of semaglutide or placebo for 24 weeks, followed by a safety evaluation. The study is motivated by an analysis published in March 2026, led by Ziyad Al-Aly of the United States — VA St. Louis Health Care System, which found that patients taking GLP-1 medications had lower rates of alcohol and other substance use disorders. VA Secretary Doug Collins emphasized the department's unique position to conduct such research. Recruitment began July 28, 2026. The trial is not yet approved by the United States — Food and Drug Administration for this indication, and the VA cautioned veterans against self-medicating.